Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection

J Antimicrob Chemother. 2009 Oct;64(4):871-3. doi: 10.1093/jac/dkp263. Epub 2009 Jul 22.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Anti-HIV Agents / pharmacokinetics
  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use*
  • Antitubercular Agents / pharmacokinetics
  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use*
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • Lopinavir
  • Male
  • Pyrimidinones / pharmacokinetics
  • Pyrimidinones / pharmacology
  • Pyrimidinones / therapeutic use*
  • Rifabutin / pharmacokinetics
  • Rifabutin / pharmacology
  • Rifabutin / therapeutic use*
  • Ritonavir / pharmacokinetics
  • Ritonavir / pharmacology
  • Ritonavir / therapeutic use*
  • Serum / chemistry
  • Tuberculosis / drug therapy*
  • Young Adult

Substances

  • Anti-HIV Agents
  • Antitubercular Agents
  • Pyrimidinones
  • Rifabutin
  • Lopinavir
  • Ritonavir